AAN 2023: Rozanolixizumab yields benefits across gMG patient groups
People with generalized myasthenia gravis (gMG) treated with the experimental therapy rozanolixizumab in a clinical trial generally experienced…
Articles by Marisa Wexler, MS
AAN 2023: Vyvgart for 2 years seen to ease symptoms of gMG in study
Treatment with Vyvgart (efgartigimod alfa-fcab) over two years was found to safely and effectively ease symptoms of…
AAN 2023: Zilucoplan eases symptoms in all subgroups in trial
Treatment with the experimental therapy zilucoplan eased symptoms of generalized myasthenia gravis (gMG) across different subgroups of patients…
Robot-assisted thymectomy ‘safe and feasible’ in MG: Study
Robot-assisted surgery to remove the thymus is generally safe for people with myasthenia gravis (MG), with most patients who…
Navigating the US health insurance system is topic of panel discussion
For people with rare health conditions like myasthenia gravis (MG), navigating the U.S. health insurance system can be difficult,…
‘Life-hacking,’ self-care, and staying active at core of living with MG
Life with myasthenia gravis (MG) often means finding new ways to do things that used to be easy but…
Patients Rising director stresses importance of self-advocacy
For people with myasthenia gravis (MG) and other chronic diseases, it’s important to be proactive in learning how to…
Hope called a ‘remedy for fear’ and powerful tool for managing MG
Maintaining a hopeful outlook is a vital part of managing myasthenia gravis (MG). Hope can help improve a person’…
Vyvgart approved as add-on in UK for adults with AChR-positive gMG
Vyvgart (efgartigimod) won approval in the U.K. as an add-on to standard therapy for adults with generalized myasthenia…
Early, aggressive treatment better for controlling MG symptoms: Study
Early and aggressive treatments tend to lead to better control of myasthenia gravis (MG) symptoms, a recent study reports.